Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Gammaretroviral and lentiviral vectors are promising tools for gene therapy, but they can be oncogenic. The development of safer vectors depends on a quantitative assay for insertional mutagenesis. Here we report a rapid, inexpensive, and reproducible assay which uses a murine cell line to measure the frequency of interleukin-3 (IL-3)-independent mutants. Lentiviral and gammaretroviral vectors cause insertional mutagenesis at similar frequencies; however, they use different mechanisms. Human immunodeficiency virus (HIV)-based vectors generate mutants by insertion only into the growth hormone receptor ( Ghr ) locus. The HIV enhancer/promoter is active in the absence of the HIV Tat protein in this locus, and an HIV/ Ghr spliced transcript expresses GHR and cells respond to GH. Deletion of the enhancer/promoter in a self-inactivating HIV-based vector prevents this mechanism of insertional mutagenesis. In contrast, gammaretroviral vectors insert into other loci, including IL-3 and genes identified as common insertion sites in the Retroviral Tagged Cancer Gene Database (RTCGD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, insertional mutagenesis has been found in clinical trials with lentiviral vectors, prompting a detailed study of genotoxicity assays of all integrated vectors [76,77].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [77]
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“For example, patients with common gamma-chain deficiency treated with a gammaretroviral vector have developed leukemia following vector insertion in oncogenic loci (13).”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 2×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundMethodTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 6×
“G18 2 N Il3 16187 11 2,607 bp downstream Cytokine/growth factor activity N Fbxo9 71538 9 3,183 bp upstream Ubiquitin-protein ligase activity N Ick 56542 5,744 bp upstream Protein kinase activity, signal transduction Control CNCG 2 1 Y Tpm3 59069 3 8,408 bp, intron 2-3 Regulation of muscle contraction 1 CNCG 6 1 N Mll2…”
BackgroundMethodInfluentialOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051 · cited 2×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundRetroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences
Mitchell, R. S., Beitzel, B. F., Schroder, A. R. W., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., & Bushman, F. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020234 · Cited by 976 · cited 1×
“However, MLV tends to integrate near the transcription start site, and HIV shows a stronger preference for expressed genes (20, 38).”
BackgroundCorrection of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975 · cited 1×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701 · cited 1×
“Retroviral-vector insertional oncogenesis has been quantitated in mice either by using vectors expressing an oncogene (11, 18) or mutant, tumor-prone mice (22, 29).”
BackgroundA transient three-plasmid expression system for the production of high titer retroviral vectors
Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., & Kingsman, A. J. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.4.628 · Cited by 690
Palacios, R., & Steinmetz, M. (1985) · Cell · doi:10.1016/s0092-8674(85)80053-2 · Cited by 688
Gene transfer in humans using a conditionally replicating lentiviral vector
Levine, B. L., Humeau, L. M., Boyer, J., MacGregor, R.-R., Rebello, T., Lu, X., Binder, G. K., Slepushkin, V., Lemiale, F., Mascola, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608138103 · Cited by 501 · cited 1×
“In a recent AIDS gene therapy clinical trial, a WT HIV-1 LTR lentiviral vector was used to drive antisense RNA against the HIV-1 envelope, so that Tat would activate expression in HIVinfected cells (17).”
MethodDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Rivière, I., Brose, K., & Mulligan, R. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6733 · Cited by 364 · cited 1×
“fluorescent protein) (26) (the latter kindly provided by J.”
BackgroundRTCGD: retroviral tagged cancer gene database
Akagi, K. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh013 · Cited by 324 · cited 8×
“Ghr is also likely to participate in primary cell transformation by retroviruses as it is defined as a CIS, appearing six times in the RTCGD (2).”
BackgroundInfluentialTherapeutic gene causing lymphoma
Woods, N.-B., Bottero, V., Schmidt, M., von Kalle, C., & Verma, I. M. (2006) · Nature · doi:10.1038/4401123a · Cited by 288 · cited 1×
“It remains unclear whether the common gamma-chain itself or the rapid proliferation caused by its restoration predisposes these particular patients to insertional oncogenesis (25, 37).”
BackgroundClonal dominance of hematopoietic stem cells triggered by retroviral gene marking
Kustikova, O., Fehse, B., Modlich, U., Yang, M., Düllmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z., & Baum, C. (2005) · Science · doi:10.1126/science.1105063 · Cited by 283 · cited 1×
“Vector integration can also cause clonal expansion (16); in patients with chronic granulomatous disease, the expansion of vector-modified clones has improved the rate of gene correction (23).”
BackgroundCell culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., & Baum, C. (2006) · Blood · doi:10.1182/blood-2005-08-024976 · Cited by 278
A mutational assay system using the thymidine kinase locus in mouse lymphoma cells
Clive, D., Flamm, W. G., Machesko, M. R., & Bernheim, N. J. (1972) · Mutation Research · doi:10.1016/0027-5107(72)90066-8 · Cited by 261 · cited 1×
“Chemical mutagenesis results in DNA damage which can lead to loss of gene function; this can be scored by the selection of cells for the loss of an activity, for example, that of the enzyme thymidine kinase (7).”
BackgroundGrowth Hormone (GH), GH Receptor, and Signal Transduction
Kopchick, J. J., & Andry, J. M. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3068 · Cited by 231 · cited 1×
“We can detect two proteins of sizes consistent with GHR and the smaller, secreted GH binding protein, generated by alternative splicing of the 3 end of the Ghr transcript, by immunoblotting (15) (Fig.”
BackgroundInterleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents.
Collins, M. K., Marvel, J., Malde, P., & Lopez-Rivas, A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.4.1043 · Cited by 214 · cited 2×
“The suspension cell lines BAF3 (24) and Bcl15 (8) were grown in”
BackgroundSelf-citationContinuous high-titer HIV-1 vector production
Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F.-L., Mitrophanous, K., & Collins, M. (2003) · Nature Biotechnology · doi:10.1038/nbt815 · Cited by 198
Self-citationZhang, F., Thornhill, S. I., Howe, S. J., Ulaganathan, M., Schambach, A., Sinclair, J., Kinnon, C., Gaspar, H. B., Antoniou, M., & Thrasher, A. J. (2007) · Blood · doi:10.1182/blood-2006-12-060814 · Cited by 176
Carteau, S., Hoffmann, C. J., & Bushman, F. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4005-4014.1998 · Cited by 146 · cited 1×
“For inverse PCR (5), genomic DNA was digested”
Cooperating cancer-gene identification through oncogenic-retrovirus–induced insertional mutagenesis
Du, Y., Spence, S. E., Jenkins, N. A., & Copeland, N. G. (2005) · Blood · doi:10.1182/blood-2004-12-4840 · Cited by 144 · cited 1×
“tors expressing an oncogene (11, 18) or mutant, tumor-prone”
BackgroundDNA rearrangement of a homeobox gene in myeloid leukaemic cells.
Blatt, C., Aberdam, D., Schwartz, R., & Sachs, L. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03326.x · Cited by 140 · cited 1×
“An interesting precedent which could be explained by either of these mechanisms was described for the WEHI-3B myeloid leukemia cell line, which has intracisternal A particle insertions in both the HoxB locus and the IL-3 locus and secretes IL-3 (4).”
BackgroundWilliams, S. A., Kwon, H., Chen, L., & Greene, W. C. (2007) · Journal of Virology · doi:10.1128/jvi.02074-06 · Cited by 139
Alternative Processing of Growth Hormone Receptor Transcripts
Edens, A., & Talamantes, F. J. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0347 · Cited by 135
Two Modes of c-myb Activation in Virus-Induced Mouse Myeloid Tumors
Shen-Ong, G. L. C., Morse, H. C., Potter, M., & Mushinski, J. F. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.2.380-392.1986 · Cited by 134 · cited 1×
“A similar insertional mutagenesis mechanism has been reported for retroviruses, using, for example, a cryptic splice donor within the virus to express a Myb protein (27).”
BackgroundShiramizu, B. T., HERNDIER, B. G., & McGrath, M. S. (1994) · PubMed · Cited by 127
Stocking, C., Löliger, C., Kawai, M., Suciu, S., Gough, N. M., & Ostertag, W. (1988) · Cell · doi:10.1016/s0092-8674(88)90329-7 · Cited by 110
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy
Shou, Y., Ma, Z., Lu, T., & Sorrentino, B. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603635103 · Cited by 108 · cited 1×
“Retroviral-vector insertional oncogenesis has been quantitated in mice either by using vectors expressing an oncogene (11, 18) or mutant, tumor-prone mice (22, 29).”
BackgroundStocking, C., Kollek, R., Bergholz, U., & Ostertag, W. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.17.5746 · Cited by 106 · cited 1×
“The activity of the enhancer within the U3 region of the viral LTR controls the rate and type of tumor formation (9, 31, 34, 35).”
BackgroundSuppression of leukaemia virus pathogenicity by polyoma virus enhancers
Davis, B. R., Linney, E. A., & Fan, H. (1985) · Nature · doi:10.1038/314550a0 · Cited by 82 · cited 1×
“The activity of the enhancer within the U3 region of the viral LTR controls the rate and type of tumor formation (9, 31, 34, 35).”
BackgroundVogt, M., Haggblom, C., Swift, S. E., & Haas, M. (1985) · Journal of Virology · doi:10.1128/jvi.55.1.184-192.1985 · Cited by 80 · cited 1×
“The activity of the enhancer within the U3 region of the viral LTR controls the rate and type of tumor formation (9, 31, 34, 35).”
BackgroundGene therapy: Is IL2RG oncogenic in T-cell development?
Pike-Overzet, K., de Ridder, D., Weerkamp, F., Baert, M., Verstegen, M., Brugman, M., Howe, S., Reinders, M., Thrasher, A., Wagemaker, G., et al. (2006) · Nature · doi:10.1038/nature05218 · Cited by 61
Enhancer activity correlates with the oncogenic potential of avian retroviruses.
Weber, F., & Schaffner, W. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03723.x · Cited by 56 · cited 1×
“The activity of the enhancer within the U3 region of the viral LTR controls the rate and type of tumor formation (9, 31, 34, 35).”
BackgroundBaixerás, E., Jeay, S., Kelly, P. A., & Postel-Vinay, M. C. (2001) · Endocrinology · doi:10.1210/endo.142.7.8242 · Cited by 50
Menon, R. K., Shaufl, A. L., Yu, J. H., Stephan, D. A., & Friday, R. P. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00375-0 · Cited by 44 · cited 1×
“The mouse L2 promoter is normally predominantly active in the liver, and the L1 and L5 promoters are more active in the placenta (12, 19).”
BackgroundThomas, J., Leverrier, Y., & Marvel, J. (1998) · Oncogene · doi:10.1038/sj.onc.1201672 · Cited by 25 · cited 1×
“This technique has also been performed using gammaretroviral-vector infection of the murine IL-3-dependent cell line BAF3 (24) to identify bcl-X as a molecule that inhibits apoptosis without stimulating proliferation (33).”
MethodInsertional Mutagenesis by Replication‐Deficient Retroviral Vectors Encoding the Large T Oncogene
Li, Z., Kustikova, O. S., Kamino, K., NEUMANN, T., Rhein, M., Grassman, E., Fehse, B., & Baum, C. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1392.003 · Cited by 19 · cited 1×
“tors expressing an oncogene (11, 18) or mutant, tumor-prone”
Background
Cited by
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
“The mechanism of splicing mediated activation of oncogene by LVs with active LTRs has been recently described in a cell-culture assay for insertional mutagenesis (51).”
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
“Lentivectors also exhibit insertional mutagenesis in animal models and cell-based systems prone to oncogenesis (Bokhoven et al. 2009), although overall they seem to be less mutagenic than their oncoretrovirus counterparts (Hematti et al.”
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 216
Metadata
- Authors
- Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K.
- Affiliations
- University College London (GB)
- National Institute for Medical Research (GB)
- Corresponding author
- Collins, Mary K.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2009-01
- Volume
- 83
- Issue
- 1
- Pages
- 283-294
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2612344
- OpenAlex
- W2134056794
- Semantic Scholar
- 00dac6f887ef7c0e93ed3839c2a8065d747910a7
- Cited by
- 138
- References
- 39
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 9 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 9 · 2012: 12
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Health and Safety Executive
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, lentiviral vectors, gammaretroviral vectors, gene therapy safety, oncogenicity, HIV-based vectors, self-inactivating vectors, Tat protein, insertion site mapping
- MeSH terms
- Animals, Cell Line, Genetic Vectors, Genetic Therapy, Lentivirus, Mutagenesis, Insertional, Gammaretrovirus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.